Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada

Anand Kumar; Ryan Zarychanski; Ruxandra Pinto; et al.

JAMA. published online Oct 12, 2009; (doi:10.1001/jama.2009.1496)

http://jama.ama-assn.org/cgi/content/full/2009.1496v1
Critically Ill Patients With 2009 Influenza A(H1N1) Infection in Canada

Anand Kumar, MD
Ryan Zarychanski, MD
Ruxandra Pinto, PhD
Deborah J. Cook, MD, MSc
John Marshall, MD
Jacques Lacroix, MD
Tom Stelfox, MD, PhD
Sean Bagshaw, MD, MSc
Karen Choong, MD
Francois Lamontagne, MD
Alexis F. Turgeon, MD, MSc
Stephen Lapinsky, MD
Stephane P. Ahern, MD
Orla Smith, MSc
Faisal Siddiqui, MD
Philippe Jouvet, MD, PhD
Kosar Khwaja, MD
Lauralyn McIntyre, MD, MSc
Kusum Menon, MD, MSc
Jamie Hutchison, MD
David Hornstein, MD
Ari Joffe, MD
Francois Lauzier, MD
Jeffrey Singh, MD, MSc
Tim Karachi, MD
Kim Wiebe, MD
Kendiss Olafson, MD
Clare Ramsey, MD
Satendra Sharma, MD
Peter Dodek, MD, MHSc
Maureen Meade, MD, MSc
Richard Hall, MD
Robert Fowler, MD, MSc
for the Canadian Critical Care Trials Group H1N1 Collaborative

Context Between March and July 2009, the largest number of confirmed cases of 2009 influenza A(H1N1) infection occurred in North America.

Objective To describe characteristics, treatment, and outcomes of critically ill patients in Canada with 2009 influenza A(H1N1) infection.

Design, Setting, and Patients A prospective observational study of 168 critically ill patients with 2009 influenza A(H1N1) infection in 38 adult and pediatric intensive care units (ICUs) in Canada between April 16 and August 12, 2009.

Main Outcome Measures The primary outcome measures were 28-day and 90-day mortality. Secondary outcomes included frequency and duration of mechanical ventilation and duration of ICU stay.

Results Critical illness occurred in 215 patients with confirmed (n=162), probable (n=6), or suspected (n=47) community-acquired 2009 influenza A(H1N1) infection. Among the 168 patients with confirmed or probable 2009 influenza A(H1N1), the mean (SD) age was 32.3 (21.4) years; 113 were female (67.3%) and 50 were children (29.8%). Overall mortality among critically ill patients at 28 days was 14.3% (95% confidence interval, 9.5%-20.7%). There were 43 patients who were aboriginal Canadians (25.6%). The median time from symptom onset to hospital admission was 4 days (interquartile range [IQR], 2-7 days) and from hospitalization to ICU admission was 1 day (IQR, 0-2 days). Shock and nonpulmonary acute organ dysfunction was common (Sequential Organ Failure Assessment mean [SD] score of 6.8 [3.6] on day 1). Neuraminidase inhibitors were administered to 152 patients (90.5%). All patients were severely hypoxemic (mean [SD] ratio of PaO2 to fraction of inspired oxygen [FIO2] of 147 [128] mm Hg) at ICU admission. Mechanical ventilation was received by 136 patients (81.0%). The median duration of ventilation was 12 days (IQR, 6-20 days) and ICU stay was 12 days (IQR, 5-20 days). Lung rescue therapies included neuromuscular blockade (28% of patients), inhaled nitric oxide (13.7%), high-frequency oscillatory ventilation (11.9%), extracorporeal membrane oxygenation (4.2%), and prone positioning ventilation (3.0%). Overall mortality among critically ill patients at 90 days was 17.3% (95% confidence interval, 12.0%-24.0%; n=29).

Conclusion Critical illness due to 2009 influenza A(H1N1) in Canada occurred rapidly after hospital admission, often in young adults, and was associated with severe hypoxemia, multisystem organ failure, a requirement for prolonged mechanical ventilation, and the frequent use of rescue therapies.


The reemergence of pandemic influenza has been anticipated since the Hong Kong (H3N2) influenza pandemic of 1968. In recent years, there has been substantial concern that a pandemic would involve the novel H5N1 avian flu variant, which has demonstrated an ability to cause severe disease when transmitted to humans.1,2 However, this spring the US Centers for Disease Control and Prevention reported the occurrence of a 2009 influenza A(H1N1) in 2 children in southern California.3 Subsequently, infection with this virus has been reported in virtually every country.4-7 The World Health Organization declared the first phase 6 global influenza pandemic of the century on June 11, 2009.8

Author Affiliations and a list of the Canadian Critical Care Trials Group H1N1 Collaborative Writing Committee and Clinicians appear at the end of this article. Corresponding Author: Anand Kumar, MD, Section of Critical Care Medicine, Health Sciences Centre, J1 399, 700 William Ave, Winnipeg, MB R3E-0Z3 Canada (akumar61@yahoo.com).

Caring for the Critically Ill Patient Section Editor: Derek C. Angus, MD, MPH, Contributing Editor, JAMA (angusdc@upmc.edu).
The largest numbers of confirmed cases have been documented in the United States, Mexico, Canada, Chile, and Australia. Mexico and Canada have both experienced large localized outbreaks of infection with severe illness requiring intensive care unit (ICU) admission and ventilator support. This report describes the epidemiological characteristics, clinical features, treatments, and outcomes of a multicenter cohort of critically ill adult and pediatric Canadian patients.

**METHODS**

**Study Design**

In response to an outbreak of 2009 influenza A(H1N1) in Mexico, members of the Canadian Critical Care Trials Group (CCCTG) designed a multicenter observational study of critically ill patients infected with 2009 influenza A(H1N1) (eAppendix is available at http://www.jama.com). After several cycles of feedback and pilot testing, forms were widely disseminated to ICU physicians, and uploaded to the CCCTG and other critical care society Web sites on May 3, 2009. Data were collected retrospectively or prospectively on all patients with 2009 influenza A(H1N1)–related critical illness admitted to the ICU between April 16 and August 12, 2009. Research ethics board approval was granted by Sunnybrook Health Sciences Centre as the central coordinating center on April 30, 2009, and by each participating local research ethics board. The need for a priori informed consent was waived because of the noninterventional study design.

**Data Collection**

Eligible patients included all adult and pediatric critically ill individuals admitted to participating hospitals in Canada with confirmed, probable, or suspected 2009 influenza A(H1N1) infection, according to case definitions developed by the World Health Organization and the Canadian National Microbiology Laboratory. Critically ill patients were defined as (1) those admitted to a pediatric or adult ICU or those requiring mechanical ventilation (invasive or noninvasive), (2) those with a fraction of inspired oxygen...
(FiO₂) concentration greater than or equal to 60%, or (3) those with the need for intravenous infusion of inotropic or vasopressor medication. Suspected cases of 2009 influenza A(H1N1) in the presence of a strong epidemiologic link were initially included because confirmatory testing was unavailable in some hospitals when diagnostic laboratories were overwhelmed with testing requests once the pandemic was under way.

Eligibility criteria were confirmed and data were recorded by research coordinators or site investigators at each center (eAppendix). Severity of illness was assessed in adults and children using the Acute Physiology and Chronic Health Evaluation (APACHE) II and Pediatric Risk of Mortality (PRISM) III scores.12,13 Comorbidities, including major comorbidities defined a priori, were recorded as the presence of 1 or more of the following chronic medical conditions: congestive heart failure; cerebrovascular, neoplastic, chronic liver or renal diseases; and use of immunosuppressant medications.14

The primary outcome measure was mortality at 28 days after the onset of critical illness as defined by the eligibility criteria. Secondary outcomes included frequency and duration of mechanical ventilation and duration of ICU and hospital stay. Data were submitted to the coordinating center and checked for errors by manual inspection and electronic range limits.

Analysis
Descriptive statistics included frequency analysis (percentages) for categorical variables and means and standard deviations or medians and interquartile ranges (IQRs) for continuous variables. To test for differences in baseline characteristics between those with confirmed or probable disease and those who survived vs those who died, a 2-sample t test or the Wilcoxon rank sum test was used for continuous variables as appropriate and the χ² test or Fisher exact test was used for discrete variables. Daily variables are presented at days 1, 3, 7, and 14.

The Kaplan-Meier method in which patients discharged from the ICU alive were censored at 28 days was used to depict the probability of survival over the duration of follow-up and to generate survival curves. The discriminative ability of the day 1 APACHE II and SOFA scores on mortality were compared by testing the difference in C statistics (area under the receiver operating curve). The 95% confidence intervals (CIs) and P values were reported to reflect a 2-tailed level of .05. The statistical analyses were conducted using SAS version 9.1 (SAS Institute Inc, Cary, North Carolina).

RESULTS
Characteristics of Study Patients and Hospitals
Between April 16 and July 13, 2009, 215 critically ill patients were admitted to 38 study ICUs (median of 16 ICU beds15-34, median hospital size, 463 beds [IQR, 238-524 beds]) with confirmed (n=162), probable (n=6), or suspected (n=47) 2009 influenza A(H1N1) infection. Patients having confirmed or probable 2009 influenza A(H1N1) infection were significantly younger, had a longer duration of mechanical ventilation and ICU stay, and higher mortality than those with suspected disease. Therefore, all analyses were restricted to the 168 patients with confirmed or probable 2009 influenza A(H1N1) infection (TABLE 1). The mean (SD) age was 32.3 (21.4) years; 113 patients were female (67.3%), 50 were children (29.8%), and there were 43 aboriginal Canadians (25.6%). There were 52 critically ill patients from the greater Winnipeg region, in the province of Manitoba, and 116 patients were from other provinces (FIGURE 1). Sixteen cases originated from nosocomial transmission; none of these were health care workers.

Among adults, the mean (SD) APACHE II score was 19.7 (8.7); among pediatric patients, the mean (SD) PRISM III score was 9.1 (9.8). At presentation, comorbidities were present in 165 patients (98.2%) (TABLE 2). However, major comorbidities were present in only 51 patients (30.4%). The most common individual comorbidities were chronic lung disease (41.1%), obesity (33.3%), hypertension (24.4%), and ever smoking (22.6%). The mean (SD) body mass index (BMI; calculated as weight in kilograms divided by height in meters squared).
Table 3. Organ Dysfunction Over Time Among 168 Critically Ill Patients

<table>
<thead>
<tr>
<th>Day</th>
<th>SOFA score, mean (SD)</th>
<th>Ratio of PaO2 to FiO2, mean (SD), mm Hg</th>
<th>Lowest SBP, mean (SD), mm Hg</th>
<th>Creatinine, median (IQR), mg/dL</th>
<th>Platelet count, mean (SD), x 10^9/µL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.8 (3.6)</td>
<td>147 (128)</td>
<td>95 (24)</td>
<td>0.73 (0.50-1.15)</td>
<td>189 (87)</td>
</tr>
<tr>
<td>3</td>
<td>6.6 (4.2)</td>
<td>168 (86)</td>
<td>104 (28)</td>
<td>0.74 (0.55-1.28)</td>
<td>187 (93)</td>
</tr>
<tr>
<td>7</td>
<td>6.1 (4.3)</td>
<td>172 (101)</td>
<td>107 (27)</td>
<td>0.80 (0.57-1.72)</td>
<td>283 (171)</td>
</tr>
<tr>
<td>14</td>
<td>5.7 (4.2)</td>
<td>190 (122)</td>
<td>112 (27)</td>
<td></td>
<td>404 (228)</td>
</tr>
</tbody>
</table>

Table 4. Clinical Course and Outcomes of Patients With Confirmed or Probable 2009 Influenza A(H1N1) Infection

<table>
<thead>
<tr>
<th>No. (% ) of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>[95% CI] (N = 168)</td>
</tr>
<tr>
<td>Time from ICU admission to death</td>
</tr>
<tr>
<td>Day 14</td>
</tr>
<tr>
<td>Day 28</td>
</tr>
<tr>
<td>Day 90</td>
</tr>
<tr>
<td>Time course of illness, d</td>
</tr>
<tr>
<td>Symptoms to hospital admission</td>
</tr>
<tr>
<td>Hospitalization to ICU admission</td>
</tr>
<tr>
<td>Hospitalization to death</td>
</tr>
<tr>
<td>ICU length of stay, d</td>
</tr>
<tr>
<td>Survivors</td>
</tr>
<tr>
<td>Nonsurvivors</td>
</tr>
<tr>
<td>Duration of ventilation, d</td>
</tr>
<tr>
<td>Survivors</td>
</tr>
<tr>
<td>Nonsurvivors</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; ICU, intensive care unit; IQR, interquartile range.

Outcomes

Among 168 critically ill patients with 2009 influenza A(H1N1) infection, 29 died (17.3%; 95% CI, 12.0%-24.0%). Eighteen patients died (10.7%; 95% CI, 6.6%-16.6%) within the first 14 days and 24 died (14.3%; 95% CI, 9.5%-20.7%) within 28 days from the onset of critical illness (Table 4 and Figure 2). Twenty-six (26%) and the mean (SD) day 1 positive end-expiratory pressure (PEEP) was 9.8 (4.0) cm H2O (eTable is available at http://www.jama.com).

The mean daily PEEP was greater than 10 cm H2O for the first 2 weeks of mechanical ventilation. Over the first 2 weeks of critical illness, tidal volumes ranged from 8 to 9.1 mL/kg of ideal body weight; and carbon dioxide elimination was not substantially impaired. Barotrauma occurred in 14 patients (8.3%). Therapies for oxygenation failure included neuromuscular blockade (47 patients; 28.0%), inhaled nitric oxide (23 patients; 13.7%), high-frequency oscillatory ventilation (20 patients; 11.9%), extracorporeal membrane oxygenation (7 patients; 4.2%), and prone positioning (5 patients; 3.0%) (eTable).

Inotropes or vasopressors were used in 55 patients (32.7%) on day 1 after the onset of critical illness (Table 3), often with high levels of sedatives to facilitate patient-ventilator synchrony. Drug treatments included neuromimetic inhibitors (152 patients [90.5%] for a median of 5 days*), antibiotics (166 patients; 98.8%), and corticosteroids (85 patients; 50.6%).

Creatine kinase was moderately elevated over the first week of critical illness (median level, 580 U/L [IQR, 203-1728 U/L] by day 3; to convert creatine kinase to µkat/L, multiply by 0.0167) (Table 3). The mean leukocyte count was normal at admission and remained in the normal range for the first week. Clinical evidence of secondary bacterial pneumonia following ICU admission was found in 41 cases (24.4% of all patients) including 18 cases caused by *Staphylococcus aureus* and 5 cases caused by *Streptococcus pneumoniae*.

Course of Illness and Treatments Received

The median time from symptom onset to hospital admission was 4 days (IQR, 2-7 days) and from hospitalization to ICU admission was 1 day (IQR, 0-2 days) after presentation to the hospital. Only 10 patients (6%) had received a seasonal influenza vaccination in either of the past 2 years. Most patients (70.8%) had bilateral chest radiograph infiltrates (41.1% with 4-quadrant involvement) and 72.6% had acute lung injury at the onset of critical illness.

Of all patients, 136 (81.0%) were mechanically ventilated on the first day of ICU admission; 128 (76.2%) invasively and 55 (32.7%) noninvasively. Forty-seven patients (85.4%) who received noninvasive ventilation ultimately required invasive ventilation. The mean (SD) day 1 ratio of PaO2 to FiO2 was 147 (128) mm Hg (Table 3); the mean (SD) day 1 FiO2 value was 74% (55.9%), and myalgias (40.1%). Concomitant presenting conditions included possible bacterial pneumonia (34 cases; 32.1%), hypotension requiring vasopressors (23 cases; 13.7%), asthma or chronic obstructive pulmonary disease exacerbation (23 cases; 13.7%), altered level of consciousness (17 cases; 10.1%), acute kidney injury (12 cases; 7.1%), and ischemic chest pain (5 cases; 3.0%).
of those who died were female (72.4%) and 8 were male (27.6%). Of 50 children, only 4 died (8.0%). Of 9 health care workers, 5 required mechanical ventilation and none died. The median length of ICU stay was 12 days (IQR, 5-20 days), 12 days for survivors and 10 days for nonsurvivors. One patient died on a medical ward, while all others died in the ICU.

The primary reported causes of death included severe acute respiratory distress syndrome and hypoxemia, or complications thereof; secondary infection and sepsis; multiorgan dysfunction syndrome; malignancy; chronic obstructive pulmonary disease; primary cardiac arrest; tension pneumothorax; cerebral edema; and undetermined etiologies. Pulmonary embolism was believed to be contributory but not causal in 1 death.

**Comparison of Survivors With Nonsurvivors**

Patients who died were more likely to have higher severity of illness at presentation and greater organ dysfunction (Table 5). Although this overall population was young, older patients were more likely to die. There were no statistically significant differences in female sex distribution or aboriginal vs nonaboriginal status. The APACHE II and day 1 SOFA scores were significantly associated with overall mortality (P <.001 and P =.002, respectively) and there was no difference between the predictive value of these 2 scores (C statistics: 0.757 and 0.688, respectively; P = .13). Because nearly all patients received early treatment with neuraminidase inhibitors, we were unable to investigate differences in outcome due to treatment or timing of these agents (Figure 3).

**Comparison of All Patients**

As of August 22, 2009, in the general Canadian population, among 7107 reported cases, 1441 required hospitalization (20.3%), 278 were admitted to the ICU (3.9%) (the 215 admitted by July 13, 2009, are reported in this series). In comparing characteristics of all patients infected with 2009 influenza A(H1N1) infection, patients hospitalized, those admitted to the ICU, and those who died, the median age of patients was progressively greater along this continuum and there was a progressively greater proportion of patients with at least 1 underlying medical condition. The proportion of females was greater among those admitted to the ICU and among those who died compared with those infected and those admitted to hospital. There were a greater proportion of pregnant women requiring admission to the hospital and who died compared with the proportion among all of those infected.

**COMMENT**

The spring outbreak of 2009 influenza A(H1N1) infection in Canada affected primarily young, female, and aboriginal patients without major comorbidities, and conferred a 28-day mortality of 14.3% among critically ill patients. A history of lung disease or smoking, obesity, hypertension, and smoking were more likely to die. There were no statistically significant differences in female sex distribution or aboriginal vs nonaboriginal status. The APACHE II and day 1 SOFA scores were significantly associated with overall mortality (P <.001 and P =.002, respectively) and there was no difference between the predictive value of these 2 scores (C statistics: 0.757 and 0.688, respectively; P = .13). Because nearly all patients received early treatment with neuraminidase inhibitors, we were unable to investigate differences in outcome due to treatment or timing of these agents (Figure 3).

**Table 5. Comparison of Survivors and Nonsurvivors**

<table>
<thead>
<tr>
<th></th>
<th>Survivors (n = 139)</th>
<th>Nonsurvivors (n = 29)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>30 (21)</td>
<td>42 (21)</td>
<td>.007</td>
</tr>
<tr>
<td>Female sex, No. (%)</td>
<td>92 (66)</td>
<td>21 (72)</td>
<td>.52</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ever smoker, No. (%)</td>
<td>32 (23)</td>
<td>6 (21)</td>
<td>.06</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>29 (24-39)</td>
<td>31 (28-41)</td>
<td>.33</td>
</tr>
<tr>
<td>Time course of illness, median (IQR), d</td>
<td>4 (2-7)</td>
<td>5 (3-7)</td>
<td>.21</td>
</tr>
<tr>
<td>Hospitalization to ICU admission</td>
<td>0 (0-2)</td>
<td>1 (0-3)</td>
<td>.29</td>
</tr>
<tr>
<td>Characteristics at ICU admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APACHE II score, mean (SD)</td>
<td>18 (8)</td>
<td>26 (8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ratio of PaO2 to FiO2, median (IQR), mm Hg</td>
<td>124 (80-181)</td>
<td>85 (67-166)</td>
<td>.10</td>
</tr>
<tr>
<td>Initial mean arterial pressure, median (IQR), mm Hg</td>
<td>65 (58-77)</td>
<td>68 (58-83)</td>
<td>.31</td>
</tr>
<tr>
<td>Ventilation at ICU admission, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tidal volume for ideal body weight, mL/kg</td>
<td>9.2 (2.4)</td>
<td>8.6 (2.7)</td>
<td>.36</td>
</tr>
<tr>
<td>Plateau pressure, cm H2O</td>
<td>25.6 (9.3)</td>
<td>28.0 (10.6)</td>
<td>.70</td>
</tr>
<tr>
<td>Set PEEP, cm H2O</td>
<td>9.6 (3.8)</td>
<td>10.5 (4.7)</td>
<td>.36</td>
</tr>
<tr>
<td>Organ dysfunction, median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOFA score on day 1, mean (SD)</td>
<td>6.4 (3.4)</td>
<td>8.4 (3.5)</td>
<td>.01</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.71 (0.48-1.01)</td>
<td>0.97 (0.58-2.33)</td>
<td>.005</td>
</tr>
<tr>
<td>AST, U/L</td>
<td>60 (37-125)</td>
<td>71.5 (40-207)</td>
<td>.58</td>
</tr>
<tr>
<td>White blood cell count, ×10^3/L</td>
<td>6.7 (3.8-12.1)</td>
<td>6.9 (3.7-9.5)</td>
<td>.63</td>
</tr>
<tr>
<td>Platelet count, mean (SD), ×10^3/µL</td>
<td>195 (88)</td>
<td>161 (77)</td>
<td>.05</td>
</tr>
<tr>
<td>Bilirubin, mg/dL</td>
<td>0.41 (0.23-0.76)</td>
<td>0.52 (0.29-0.93)</td>
<td>.39</td>
</tr>
<tr>
<td>Creatinine kinase, U/L</td>
<td>255 (104-1117)</td>
<td>221 (42-455)</td>
<td>.45</td>
</tr>
</tbody>
</table>

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; AST, aspartate aminotransferase; BMI, body mass index; FiO2, fraction of inspired oxygen; ICU, intensive care unit; IQR, interquartile range; PEEP, positive end-expiratory pressure; SOFA, Sequential Organ Failure Assessment.

a. Calculated as weight in kilograms divided by height in meters squared.

b. Unless otherwise indicated.

**Figure 2. Age Distribution of 168 Critically Ill Patients With Confirmed or Probable 2009 Influenza A(H1N1)**

Intervals on the x-axis are equal to the lower limit and less than the upper limit of that age category.
diabetes were the most common co-morbidities. Critical illness occurred rapidly after hospital admission and was associated with severe oxygenation failure, a requirement for prolonged mechanical ventilation, and the frequent use of rescue therapies.

We identified unusual features of severe disease in the current pandemic compared with most previous well-characterized pandemics, including the (probable) H2N2 1890 Russian influenza pandemic, the H2N2 1957 Asian influenza pandemic, and the H3N2 1968 Hong Kong pandemic. In these previous influenza pandemics, an increased predilection for infection among children and young adults has been documented, although mortality curves were U shaped with increased deaths in the very young and the aged.

Our data suggest that severe disease and mortality in the current outburst is concentrated in relatively healthy adolescents and adults between the ages of 10 and 60 years, a pattern reminiscent of the W-shaped curve previously seen only during the 1918 H1N1 Spanish pandemic. Few patients older than 60 years in this study were admitted to the ICU (Figure 1). A potential biological basis for this observation is that patients in this age group have a cross-reactive antibody to 2009 influenza A(H1N1) at much higher rates than younger patients. The increased fraction of the aboriginal community presenting with severe 2009 influenza A(H1N1) infection is notable but not unique. This finding is reflected in the history of the 1918 H1N1 Spanish influenza pandemic during which mortality in aboriginal communities in North America (3%-9%) was many times higher than nonaboriginal communities (generally <0.75%).

In 1918, mortality within Alaskan and Labrador Inuit populations was 30% to 90%. Although mortality was not substantially greater among aboriginal Canadians in this report, the number of patients with severe disease and knowledge of prior illness patterns in this community is cause for concern.

The tendency of females to develop severe 2009 influenza A(H1N1) infection in this series is striking. A general female susceptibility has not been observed in other influenza case series of variable severity including the initial reports of 2009 influenza A(H1N1) infections. In most infectious diseases and related conditions such as sepsis and septic shock, males represent a larger proportion of cases and have a higher mortality. The explanation for increased risk of severe disease and death among females in this report is unclear but the role of pregnancy as a risk factor has been noted in previous influenza pandemics.

The most common co-morbidities among critically ill patients in our study were lung disease, obesity, hypertension, and a history of smoking or diabetes, each occurring in 30% to 40% of patients. All these conditions are known to be increased in frequency in the aboriginal population that comprises a substantial portion of cases within this cohort. The extent to which these co-morbidities contribute to severity of disease is unclear because a large portion of the aboriginal population (which may be a risk factor itself on the basis of genetic susceptibility) often have such co-morbidities.

Among critically ill patients, obesity has been shown to be a risk factor for increased morbidity, but not consistently with mortality. The association of obesity with severe 2009 influenza A(H1N1) infection has been reported by others and may be a novel finding of this pandemic; however, even though obesity was more common in our series than in the general Canadian population (33% vs approximately 24%), we did not find a significant difference in BMI between survivors and nonsurvivors.

Critically ill patients with diabetes and hyperglycemia also are known to be at increased risk of complications and death; similarly, alcohol abuse, which is known to be a risk factor for acute respiratory distress syndrome, may have been a risk factor for some patients in our series. These relationships also have been reported with seasonal influenza. The relative absence of serious co-morbidities emphasizes that young, relatively healthy adults were the primary population affected by severe 2009 influenza A(H1N1) infection during this outbreak.

Patients with 2009 influenza A(H1N1) infection–related critical illness experienced symptoms for an average of 4 days prior to hospital presentation, but rapidly worsened and required care in the ICU within 1 to 2 days. Apart from the usual symptoms seen in seasonal influenza, these cases stand out for the presence of gastrointestinal tract symptoms, dyspnea, purulent sputum production, and occasional frothy lung fluid on cough or endotracheal aspiration. Chest radiographs demonstrating bilateral mixed interstitial or alveolar infiltrates were found in three-quarters of the patients.

Approximately one-third of patients required vasoressor support on day 1 following ICU admission; however, in many cases this appeared temporally associated with the need for substantial sedation to optimize ventilation. Broad-spectrum antibacterial agents were initiated in almost all patients because of the initial suspicion of community-acquired bacterial pneumonnia. However, actual bacterial lung infection was typically documented later in the course of critical illness.
In Winnipeg, Manitoba, Canada, site of the largest pandemic cohort of patients, the capacity for the care of critically ill patients was seriously challenged at the outbreak peak in June (Figure 1) with full occupancy of all regional ICU beds, similar to the 2002 Toronto, Ontario, Canada, experience with severe acute respiratory syndrome.11 If, as expected, the prevalence of 2009 influenza A(H1N1) infection increases with the upcoming flu season, there will be an acutely increased demand for ICU care, including the need for rescue therapies that are not currently widely available.44-46 Clinicians and policy makers will need to examine feasible methods to optimally expand and deploy ICU resources to meet this need.

This study has a number of strengths. It represents the largest series of patients with severe 2009 influenza A(H1N1) infection yet described, and includes both adults and children from geographically and racially diverse settings across Canada, which improves the generalizability of our results to other regions. These observations of the epidemiological risk factors, typical clinical features, response to therapy, and prognosis should aid in the recognition, diagnosis, and clinical management of such infections. Our finding that patients can often be supported through 2009 influenza A(H1N1) infection–related critical illness with prolonged, aggressive life support, and the expectation that the number of cases will likely increase substantially over the next 6 months, highlight important potential limitations in critical care capacity.

This study also has limitations. Our focus on severe disease requiring ICU admission may not reflect important presenting features in less severe cases. The ongoing deaths throughout the course of the study period suggest the possibility of late deaths after the observation period. This may result in a final hospital mortality rate that exceeds the mortality rate we are reporting. Although we describe cases in most regions of Canada, many were from an outbreak in a single province (Mani toba) and involved an aboriginal Canadian population near Winnipeg, which is Manitoba’s largest city. This may lead to overrepresentation or underrepresentation of certain comorbidities and clinical features.

In conclusion, we have demonstrated that 2009 influenza A(H1N1) infection–related critical illness predominately affects young patients with few major comorbidities and is associated with severe hypoxemic respiratory failure, often requiring prolonged mechanical ventilation and rescue therapies. With such therapy, we found that most patients can be supported through their critical illness.

**Published Online:** October 12, 2009 (doi:10.1001/jama.2009.596).

**Author Affiliations:** Section of Critical Care Medicine, Health Sciences Centre and St Boniface Hospital, Winnipeg, Manitoba, Canada (Drs Kumar, Siddiqui, Wiebe, Olafson, Ramsey, and Sharma); Department of Medical Oncology and Hematology, Cancercare Manitoba, Winnipeg (Dr Zarychanski); Sunnynbrook Health Sciences Centre, Toronto, Ontario, Canada (Drs Pinto and Fowler); Departments of Clinical Epidemiology and Biostatistics (Drs Cook and Meade) and Medicine (Dr Karachi), McMaster Children’s Hospital (Dr Choong), McMaster University, Hamilton, Ontario, Canada; Department of Critical Care Medicine, St Michael’s Hospital, Toronto, Ontario, Canada (Dr Marshall and Ms Smith); Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada (Drs Lacroix and Jouvet); Departments of Critical Care Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (Dr Stelfox); Division of Critical Care Medicine, University of Alberta, Edmonton (Drs Bagshaw and Joffe); Department of Medicine, Centre Hospitalier, Université de Sherbrooke, Sher brooke, Quebec, Canada (Dr Lamontagne); Centre de Recherche du CHA, Hôpital de l’Enfant-Jésus, Université Laval, Quebec City, Quebec, Canada (Drs Turgeon and Lauzier); Intensive Care Unit, Mount Sinai Hospital (Dr Lapinsky) and University Health Network (Dr Tubbs, Toronto, Ontario, Canada); Department of Medicine, Hôpital Maisonneuve-Rosemont, University of Montréal, Montréal, Quebec, Canada (Dr Ahern; Trauma Services, McGill University Health Centre, Montréal, Quebec, Canada (Dr Khwaja); Clinical Epidemiology Unit, Ottawa Health Research Institute, Ottawa, Ontario, Canada (Dr McIntyre); Clinical Research Unit, Children’s Hospital of Eastern Ontario, Ottawa, Ontario, Department of Critical Care Medicine, Hospital for Sick Children, Toronto, Ontario, Canada (Dr Hutchison); SMBD-Jewish General Hospital, Montréal, Quebec, Canada (Dr Hornstein); University of British Columbia, Vancouver (Dr Dodek); and Department of Anesthesiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada (Dr Hall).

**Author Contributions:** Drs Kumar and Fowler had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Sharma, Meade, Fowler. Drafting of the manuscript: Kumar, Zarychanski, Pinto, Cook, Ahern, Hall, Fowler. Critical revision of the manuscript: for important intellectual content: Kumar, Zarychanski, Pinto, Cook, Marshall, Lacroix, Stelfox, Bagshaw, Choong, Lamontagne, Turgeon, Lapinsky, Ahern, Smith, Siddiqui, Khwaja, McIntyre, Menon, Hutchinson, Hornstein, Joffe, Lauzier, Singh, Karachi, Ramsey, Sharma, Meade, Hall, Fowler. Analysis and interpretation of data: Kumar, Zarychanski, Pinto, Cook, Lacroix, Stelfox, Ahern, Menon, Wiebe, Olafson, Ramsey, Sharma, Fowler. Financial Disclosures: None reported.

**Funding/Support:** The Public Health Agency of Canada, the Ontario Ministry of Health and Long-term Care, the Heart and Stroke Foundation Canada, and the Canadian Institutes of Health Research provided support for this article.

**Role of the Sponsor:** The Public Health Agency of Canada, the Ontario Ministry of Health and Long-term Care, the Heart and Stroke Foundation Canada, and the Canadian Institutes of Health Research had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

**Canadian Critical Care Trials Group H1N1 Collaborative Writing Committee:** Anand Kumar, Ryan Zarychanski, Ruxandra Pinto, Philippe Jouvet, Jacques Lacroix, John Marshall, Deborah J. Cook, Rob Fowler.

**Canadian Critical Care Trials Group H1N1 Collaborative Clinicians:** Nova Scotia: Halifax: Richard Hall, Rob Green, Dietrich Heinzler, Lisa Julien, Debra Wright (Queen Elizabeth II Health Sciences Centre); Québec: Québec City: François Lauzier, Alexis Turgeon, Caroline Roy (CHA-Hôpital de l’Enfant-Jésus); François Lelouche, Marie-Claude Ferland (Institut Universitaire de Cardiologie et de Pneumologie de Québec). Longueuil: Germain Poirier, Thomas Lemoyne. Sherbrooke: François Lamontagne (Centre Hospitalier Universitaire de Sherbrooke).
CRITICALLY ILL PATIENTS WITH 2009 INFLUENZA A(H1N1) IN CANADA

treal: Phillippe Jouvet, Jacques Lacroix (CHU Sainte-Justine; Clinical Research Institute of Montreal; Jewish General Hospital); Kosar Khwaja, Laura Banci (McGill University Health Centre); Stéphane P. Ahern, Yoanna Skrobic, Johanne Harvey (Hôpital Moun
tneux; Hôpital du Sacré-Coeur de Montréal); Isabel Alba, Manuel E. Canto (Hôpital du Sacré-Coeur de l’Ontario); Ot
tawa: Lauana Cunha, Claire Gaudet, Ray Saginur, Joe Paliargi, Irene Watpool, Tracy McCarde (Ot
tawa Hospital); Kusum Menon, Dermot Doherty, Sonny Dhanani, Roxanne Ward (Children’s Hospital of Eastern Ontario). Kingston: John Muscedere, Nicole Godfrey, Susan Fleury (Kingston General Hospital). Toronto: Robert Fowler, Ruxandra Pinto, Neil Adhi
tkari (Sunnybrook Hospital); Stephen Lapointe, Cheryl Ethier, Tom Stewart (Mount Sinai Hospital); Olfa Smith, John Marshall, Jan Friedrich, Karen Burns (St Michae
l’s Hospital); Jeffrey M. Singh, John Granton, Nancy Brockest, Andrea Matte (University of Toronto Interdepartmental Division of Critical Care Medicine); and Rachel Rodin, MD (Ap
ticaCare Medicine). The persons listed in this section are representative of the many health care professionals who have delivered ex

REFERENCES
1. Tran TH, Nguyen TL, Nguyen TD, et al; World Health Organization International Avian Influenza Investiga
ciated with increased morbidity but not mortality in criti
23. Sakr Y, Madi C, Filippescu D, et al. Obesity is asso
ciated with increased morbidity but not mortality in criti